1. Kalia S, Dutz JP: New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther 20:160-174, 2007
4. Kaufmann AM, Krise JP: Lysosomal sequestration of amine-containing drugs: Analysis and therapeutic implications. J Pharm Sci 96:729-746, 2007
5. Boya P et al. Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by
hydroxychloroquine.
Oncogene 22:3927, 2003
[PubMed: 12813466]
6. Ohkuma S, Poole B: Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc Natl Acad Sci USA 75:3327-3331, 1978
7. Nowell J, Quaranta V:
Chloroquine affects biosynthesis of Ia molecules by inhibiting dissociation of invariant (gamma) chains from alpha-beta dimers in B cells.
J Exp Med 162:1371-1316, 1985
9. Accapezzato D et al:
Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo.
J Exp Med 19:817, 2005
10. Churchill PC et al: Quinacrine antagonizes the effects of Na,K-ATPase inhibitors on renal prostaglandin E2 release but not their effects on renin secretion.
Life Sci 36:277, 1985
[PubMed: 2981387]
11. Norris DA, Weston WL, Sams WM: The effect of immunosuppressive and anti-inflammatory drugs on monocyte function in vitro.
J Lab Clin Med 90:569, 1977
[PubMed: 894108]
13. Van den Borne BE et al:
Chloroquine and
hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells.
J Rheumatol 24:55, 1997
14. Sperber K et al: Selective regulation of cytokine secretion by
hydroxychloroquine: Inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells.
J Rheumatol 20:803, 1993
[PubMed: 8336306]
15. Fox R: Anti-malarial drugs: Possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus 5:S4, 1996
16. Macfarlane DE, Manzel L: Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine,
chloroquine, and structurally related compounds.
J Immunol 160:1122, 1998
[PubMed: 9570525]
17. Strekowski L et al: Structure activity relationship analysis of substituted 4-quinolinamines, antagonists of immunostimulatory cpG-oligodeoxynucleotides.
Bioorg Med Chem 9:1819, 1999
[PubMed: 10406648]
s
18. Hugosson E et al:
Chloroquine enhances the number of IL-10 producing cells and the expression of B7-2 and ICAM-1 in in vitro-cultured PBMC.
Scand J Immunol. 55:399, 2002
[PubMed: 11967122]
19. Horrobin DF et al: Quinacrine is a prostaglandin antagonist.
Biochem Biophys Res Comm 76:1188, 1977
[PubMed: 901469]
20. Dise CA et al: Direct interaction of mepacrine with erythrocyte and platelet membrane phospholipid.
J Biol Chem 257:4701, 1982
[PubMed: 6802839]
21. David-Dufilho, M. et al: Quinacrine increases endothelial nitric oxide release: role of superoxide anion. Eur J Pharmacol 436:159, 2002
22. Hurst NP et al. Differential effects of mepacrine,
chloroquine, and
hydroxychloroquine on superoxide anion generation, phospholipid methylation and arachidonic acid release by human blood monocytes.
Biochem Pharmacol 35:3089, 1986
23. Lafyatis R, York M, Marshak-Rothstein A: Antimalarial agents: Closing the gate on Toll-like receptors? Arthritis Rheum 54:3068-3070, 2006
24. Ronnblom L, Alm GV: An etiopathogenic role for the type I IFN system in SLE. Trends Immunol 22:427-431, 2001
25. Nakano S et al: Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus. Rheumatology (Oxford) 47:145-149 2008
26. Latz E et al: TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 5:190-198, 2004
27. Wallace D: Antimalarial therapies. In: Dubois' Lupus Erythematosus, 5th edition, edited by D Wallace, B Hahn. Philadelphia, Lippincot Williams & Wilkins, 1997, pp. 1117-1138.
28. Sams WM, Epstein JH, Winkelmam RK: Solar urticaria-investigation of pathogenetic mechanisms.
Arch Dermatol 99:390, 1969
[PubMed: 5769324]
29. Wozniacka A et al:
Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients.
Lupus 15:268-275, 2006
30. Sjolin-Forsberg G et al: Topical
chloroquine applied before irradiation protects against ultraviolet B (UVB)- and UVA-induced erythema but not against immediate pigment darkening.
Photodermatol Photoimmunol Photomed 9:220, 1992
[PubMed: 1342192]
31. Woodburne AR, Philpott OS, Philpott JA: Quinacrine (atabrine) in treatment of solar dermatoses. Arch Dermatol Syphil 16:118, 1951
32. Nguyen TQ et al: 4-Aminoquinoline antimalarials enhance UV-B induced c-jun transcriptional activation.
Lupus 7:148, 1998
[PubMed: 9607637]
33. Kurnick NB, Radcliffe IE: Reaction between DNA and quinacrine and other anti-malarials.
J Lab Clin Med 60:669, 1962
[PubMed: 13927514]
34. Cohen SN, Yielding KL: Stabilization of the structure of native DNA by
chloroquine and observations on the nature of the chloroquine-DNA complex.
Arthritis Rhem 6:767, 1963
35. O'Brien RL et al: Reactions of
quinine,
chloroquine, and quinacrine with DNA and their effects on DNA and RNA polymerase reactions.
Proc Natl Acad Sci 55:1511, 1966
[PubMed: 5336287]
36. Dubois EL: Effect of quinacrine (Atabrine) upon lupus erythematosus phenomenon.
Arch Dermatol 71:570, 1955
[PubMed: 14360779]
37. Wallace DJ et al: Cholesterol lowering effect of
hydroxychloroquine in patients with rheumatic disease: Reversal of deleterious effects of steroids on lipids.
Am J Med 89:322, 1990
[PubMed: 2393036]
38. Smith GK et al: Effect of
chloroquine on
insulin and glucose homeostasis in normal subjects and patients with non-insulin-dependent diabetes mellitus.
BMJ 294:465, 1987
[PubMed: 3103729]
39. Quatraro A et al:
Hydroxychloroquine in decompensated, treatment refractory non-insulin-dependent diabetes mellitus: A new job for an old drug.
Ann Intern Med 112:678, 1990
[PubMed: 2110430]
40. Jancinova V, Nosal R, Pterikova M: On the inhibitory effect of
chloroquine on blood platelet aggregation.
Thromb Res 74:495, 1994
[PubMed: 8085250]
41. Ferrante A et al: Depression of human polymorphonuclear leukocyte function by antimalarial drugs.
Immunology 58:125, 1986
[PubMed: 2423436]
42. Lagneaux L et al: Early induction of apoptosis in B-chronic lymphocytic leukaemia cells by
hydroxychloroquine: Activation of caspase-3 and no protection by survival factors.
Br J Haematol 112:344, 2001
[PubMed: 11167827]
44. Jiang MC, Lin JK, Chen SS: Inhibition of HIV-1 Tat-mediated transactivation by quinacrine and
chloroquine.
Biochem Biophys Res Comm 226:1, 1996
[PubMed: 8806583]
46. Savarino A et al: New insights into the antiviral effects of
chloroquine.
Lancet Infect Dis 6:67-69, 2006
47. Tett SE: Clinical pharmacokinetics of slow acting antirheumatic drugs.
Clin Pharmacokinet 25:392, 1993
[PubMed: 7904547]
48. United States Pharmacopeial Convention:
Chloroquine, in
Drug Information for the Health Care Professional, 20th edition, 2000, p. 876
49. Unites States Pharmacopeial Convention:
Hydroxychloroquine. In:
Drug Information for the Health Care Professional, 20th edition, 2000, p. 1735
50. Unites States Pharmacopeial Convention: Quinacrine. In: Drug Information for the Health Care Professional, 18th edition, 1998, p 2469.
51. Ducharme J, Farinotti R: Clinical pharmacokinetics and metabolism of
chloroquine. Focus on recent advancements.
Clinical Pharmacokinet 31:257, 1996
[PubMed: 8896943]
53. Tett SE et al: A dose ranging study of the pharmacokinetics of
hydroxychloroquine following intravenous administration to healthy volunteers.
Br J Clin Pharmacol 26:303, 1988
[PubMed: 3179169]
55. Rahman P et al: Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus.
J Rheumatol 25:1716, 1998
[PubMed: 9733451]
56. Schein JR: Cigarette smoking and clinically significant drug interactions.
Ann Pharmacol 29:1139, 1995
[PubMed: 8573960]
57. Costedoat-Chalumeau N et al: Low blood concentration of
hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus.
Arthritis Rheum 54:3284-3290, 2006
58. Griffin JP: Drug interactions with antimalarial agents.
Adverse Drug React Toxicol Rev 18:25, 1999
[PubMed: 10401521]
59. Ang GC, Werth V: Combination antimalarials in the treatment of cutaneous dermatomyositis: A retrospective study.
Arch Dermatol 141:855, 2005
[PubMed: 16027300]
60. Davidson AM, Birt AR:
Quinine bisulfate as a desensitizing agent in the treatment of lupus erythematosus.
Arch Dermatol 37:247, 1938
61. Page F: Treatment of lupus erythematosus with mepacrine.
Lancet 2:755, 1951
[PubMed: 14874500]
62. Kraak JH et al: The value of
hydroxychloroquine (Plaquenil) for treatment of chronic discoid lupus erythematosus: A double blind trial.
Dermatologica 130:293, 1965
[PubMed: 14333636]
63. Wallace DJ: The use of quinacrine (Atabrine) in rheumatic diseases: A reexamination.
Semin Arthritis Rheum 18:282, 1989
[PubMed: 2658071]
64.
A randomized study of the effect of withdrawing
hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian
Hydroxychloroquine Study Group.
N Engl J Med324: 150-154, 1991
65. Martens PB, Moder KG, Ahmed I: Lupus panniculitis: Clinical perspectives from a case series. J Rheumatol 26:68-72, 1999
66. Cavazzana I et al: Treatment of lupus skin involvement with quinacrine and
hydroxychloroquine.
Lupus 18:735-739, 2009
67. Norris P et al: The role of interleukins 1, 6, and 8 as lymphocyte attractants in the photodermatoses polymorphic light eruption and chronic actinic dermatitis.
Clin Exp Dermatol 24:321, 1999
[PubMed: 10457140]
68. Cahn MM et al: Polymorphous light eruption—The effect of
chloroquine phosphate in modifying reactions to ultraviolet light.
J Invest Dermatol 26:201, 1956
[PubMed: 13319807]
70. Jensen CT: Oral carotenoid treatment in polymorphous light eruption. A cross-over comparison with oxychloroquine and placebo. Photodermatology 2:166, 1985
71. Murphy GM, Hawk JL, Magnus IA:
Hydroxychloroquine in polymorphic light eruption: A controlled trial with drug and visual sensitivity monitoring.
Br J Dermatol 116:379-386, 1987
72. Corbett MF et al: Controlled therapeutic trials in polymorphic light eruption. Br J Dermatol 107:571-581, 1982
74. Baler GR. Porphyria precipitated by
hydroxychloroquine treatment of systemic lupus erythematosus.
Cutis 17:96-98, 1976
75. Chinarro S et al: Studies on “in vitro” formation of complexes between porphyrins and
chloroquine.
Biochem Int 6:565, 1983
[PubMed: 6679724]
76. Cripps DJ, Curtis
AC: Toxic effect of
chloroquine on porphyria hepatica.
Arch Dermatol 86:575, 1962
78. Valls V, Ena J, Enriquies-de-Salamanca R: Low dose oral
chloroquine in patients with porphyria cutanea tarda and low-moderate iron overload.
J Dermatol Sci yy:169, 1994
79. Malkinson FD, Levitt L:
Hydroxychloroquine treatment of porphyria cutanea tarda.
Arch Dermatol 108:779, 1973
80. Swanbeck G, Wennersten G: Treatment of porphyria cutanea tarda with
chloroquine and phlebotomy.
Br J Dermatol 4:77, 1977
81. British Tuberculosis Association.
Chloroquine in the treatment of sarcoidosis. A report from the research committee of the British Tuberculosis Association.
Tubercule 48: 257-272, 1967
82. Badgwell C, Rosen T: Cutaneous sarcoidosis therapy updated. J Am Acad Dermatol 56:69-83, 2007
83. Siltzbach LE, Teirstein AS:
Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis.
Acta Med Scand Suppl 425:302-308, 1964
84. Morse SI: The treatment of sarcoidosis with
chloroquine.
Am J Med 30:779-784, 1961
85. Zic JA: Treatment of cutaneous sarcoidosis with
chloroquine. Review of the literature.
Arch Dermatol 127:1034-1040, 1991
86. Jones E, Callen JP.
Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas.
J Am Acad Dermatol 23:487-489, 1990
87. Fox RI, Kang HI: Mechanism of action of antimalarial drugs: Inhibition of antigen processing and presentation. Lupus 2(Suppl. 1):S9-S12, 1993
88. Wallace DJ: The use of
chloroquine and
hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus. A critical review.
Lupus 5:S59, 1996
90. Zic JA et al: Treatment of cutaneous sarcoidosis with
chloroquine: Review of the literature.
Arch Dermatol 127:1034, 1991
[PubMed: 2064404]
92. Simon M, Jr., von den Driesch P: Antimalarials for control of disseminated granuloma annulare in children. J Am Acad Dermatol 31:1064-1065, 1994
93. Masmoudi A et al: [Beneficial effects of antimalarials in the treatment of generalized granuloma annular in children]. Tunis Med 84:125-127, 2006
94. Eisen D:
Hydroxychloroquine sulfate (Plaquenil) improves oral lichen planus: An open trial.
J Am Acad Dermatol 28:609-612, 1993
95. Wolf R, Wolf D, Ruocco V. Antimalarials: Unapproved uses or indications. Clin Dermatol 18:17-35, 2000
96. Baer TW: Epidermolysis bullosa hereditaria treated with antimalarials. Arch Dermatol 84:503-504, 1961
97. Doring HF, Mullejans-Kreppel U: [Chloroquine–therapy of atopic dermatitis]. Z Hautkr 62:1205-1213, 1987
98. Lakhanpal S et al: Eosinophilic fasciitis: Clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum 17:221-231, 1988
99. Nagy E, Ladanyi E: [Treatment of circumscribed scleroderma in childhood]. Z Hautkr; 62:547-549, 1987
100. Lopez LR et al: The hypocomplementemic urticarial-vasculitis syndrome: Therapeutic response to
hydroxychloroquine.
J Allergy Clin Immunol 73:600-603, 1984
101. Marmor MF, Kellner U, Lai TY, Lyons JJ, Mieler WF: American Academy of Ophthalmology. Ophthalmology 118(2): 415-422, 2011
102. Sfikakis PP, Mavrikakis M: Ophthalmologic monitoring for antimalarial toxicity. J Rheumatol 31:1011-1012, 2004; author reply 2
105. Wallace DJ: Antimalarial drugs.
Rheum Dis Clin North Am 20:243, 1994
[PubMed: 8153401]
106. Rious B et al: Treatment of severe
chloroquine poisoning.
N Engl J Med 318:1, 1988
113. Schmid I et al: Marrow transplantation for severe aplastic anemia associated with exposure to quinacrine.
Blut 61:52, 1990
[PubMed: 2207341]
114. Bauer F: Quinacrine hydrochloride drug eruption (topical lichenoid dermatitis).
J Am Acad Dermatol 4:239, 1981
[PubMed: 6452466]
115. Wolf R, Ruocco V: Triggered psoriasis. Adv Exp Med Biol 445:221, 1999
116. Slagel GA, James WD: Plaquenil-induced erythroderma.
J Am Acad Dermatol 12: 857, 1985
[PubMed: 3159760]
117. Wintroub BU, Stern R: Cutaneous drug reactions. Pathogenesis and clinical classification.
J Am Acad Dermatol 13:167, 1985
[PubMed: 2931455]
118. Granstein RD, Sober AJ: Drug-and heavy metal-induced hyperpigmentation.
J Am Acad Dermatol 5:1, 1981
[PubMed: 6268671]
119. Daniel CR, Scher RK: Nail changes caused by systemic drugs or ingestants.
Derm Clinics 3:491, 1985
[PubMed: 3830510]
122. Hobbs RF, Calnan CD: Visual disturbances with anti-malarial drugs with particular reference to
chloroquine keratopathy.
Arch Dermatol 80:557, 1959
[PubMed: 14402142]
124. Mackenzie AH: Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med 18:40, 1982
125. Browning DJ: Bull's-eye maculopathy associated with quinacrine therapy for malaria.
Am J Ophthal 137:577, 2004
[PubMed: 15013892]
130. Creel N, Werth V: Rhabdomyolysis associated with quinacrine therapy in a patient with chronic cutaneous lupus erythematosus.
J Drugs in Dermatol 4:225, 2005
[PubMed: 15776783]
132. Rahman P et al: Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus.
J Rheumatol 25:1716, 1998
[PubMed: 9733451]
134. Del C, Battle AM et al: Two cases of infantile porphyria cutanea tarda: Successful treatment with S-adenosyl-L-methionine and low dose oral
chloroquine.
Br J Dermatol 116:407, 1987
137. Ziering CL, Rabinowitz LG, Esterly NB: Antimalarials for children. Indications, toxicities, and guidelines.
J Am Acad Dermatol 28:764, 1993
[PubMed: 8496422]
138. Lewis R et al: Malaria associated with pregnancy.
Obstet Gynecol 42:696, 1973
[PubMed: 4584194]
141. Khamashta MA et al: The use of
hydroxychloroquine in lupus pregnancy: The British experience.
Lupus 5:S65, 1996
142. Parke AL, Rothfield NF: Antimalarial drugs in pregnancy—The North American experience. Lupus 5:S67, 1996
143. Parke AL. Antimalarial drugs in pregnancy.
Scand J Rheum 107:125, 1998.
[PubMed: 9759150]
144. Motta M et al: Antimalarial agents in pregnancy.
Lancet 359:524, 2002
[PubMed: 11853823]
146. Costedoat-Chalumeau N et al: Safety of
hydroxychloroquine in pregnant patients with connective tissue disease.
Arthritis Rheum 11:3207, 2003
147. Costedoat-Chalumeau N et al: Safety of
hydroxychloroquine in pregnant patients with connective tissue disease. Review of the literature.
Autoimmunity Rev 4:111, 2005
[PubMed: 15722258]
148. Parke AL: Antimalarial drugs, pregnancy and lactation. Lupus 2:S21, 1993
149. Canadian Rheumatology Association: Canadian Consensus Conference on
hydroxychloroquine.
J Rheumatol 27:2919, 2000